Skip to main content

Advertisement

Table 1 Summary of clinical studies on monoclonal antibodies for eosinophilic esophagitis (EoE) treatment

From: Eosinophilic esophagitis in children: doubts and future perspectives

Study Design Drug Target Population
Assa’ad et al. [70] Randomized double-blind parallel group Mepolizumab IL-5 Children (n = 59)
Otani et al. [71] Randomized double-blind single arm Mepolizumab IL-5 Children (n = 43)
Spergel et al. [72] Randomized double-blind, placebo control Reslizumab IL-5 Children (n = 226)
Arasi et al. [77] Case report Omalizumab IgE Child (n = 1)
Rocha et al. [73] Case series Omalizumab IgE Children (n = 2)
Loizou et al. [79] Non-randomized, open-label, single arm Omalizumab IgE Children and adults (n = 15)
Clayton et al. [78] Randomized double-blind, placebo control Omalizumab IgE Children and adults (n = 30)
Rothemberg et al. [62] Randomized double-blind, placebo control QAX576 IL-13 Adults (n = 25)
Straumann et al. [85] Non-randomized, open-label, single arm Infliximab TNF-alpha Adults (n = 3)
  1. IL interleukin, TNF tumor necrosis factor